Literature DB >> 11257074

Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.

W Mazur1, S F Nagueh, N M Lakkis, K J Middleton, D Killip, R Roberts, W H Spencer.   

Abstract

BACKGROUND: Hypertrophic obstructive cardiomyopathy (HOCM) is characterized by left ventricular hypertrophy (LVH) in the absence of increased external load. Recently, nonsurgical septal reduction therapy (NSRT) with intracoronary ethanol has been introduced to treat severely symptomatic patients with outflow tract obstruction. Its long-term effects on LV mass, however, are unknown. METHODS AND
RESULTS: The LV size, function, and outflow tract gradient of 26 HOCM patients (53+/-15 years old) who underwent NSRT were assessed by echocardiography at baseline and 1 and 2 years after the procedure. LVH was evaluated by wall thickness of individual myocardial segments, planimetered myocardial area, and mass. The outflow gradient decreased from 36+/-6 mm Hg before NSRT to 0+/-3 mm Hg at 2 years (P<0.001), with patients experiencing symptomatic improvement (P<0.05). LV end-diastolic and end-systolic dimensions increased significantly at both 1 and 2 years (P<0.001). All parameters of LVH showed evidence of regression. LV mass decreased (301+/-78 g at baseline, 223+/-5 g at 1 year, and 190+/-58 g at 2 years; P<0.01), with the 2-year reduction in mass related to infarct size and the acute reduction in outflow tract gradient (r=0.48, P<0.05 and r=0.63, P<0.01, respectively).
CONCLUSIONS: NSRT results in LV remodeling that is characterized by an increase in LV size and a decrease in the extent of LVH.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257074     DOI: 10.1161/01.cir.103.11.1492

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

1.  Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy.

Authors:  Marco Canepa; Lars L Sorensen; Iraklis Pozios; Veronica L Dimaano; Hong-Chang Luo; Aurelio C Pinheiro; James B Strait; Claudio Brunelli; M Roselle Abraham; Luigi Ferrucci; Theodore P Abraham
Journal:  Am J Cardiol       Date:  2013-10-15       Impact factor: 2.778

Review 2.  The diagnosis and treatment of hypertrophic cardiomyopathy.

Authors:  Christian Prinz; Martin Farr; Detlef Hering; Dieter Horstkotte; Lothar Faber
Journal:  Dtsch Arztebl Int       Date:  2011-04-01       Impact factor: 5.594

3.  Sex-related differences in left ventricular remodeling and outcome after alcohol septal ablation in hypertrophic obstructive cardiomyopathy: insights from cardiovascular magnetic resonance imaging.

Authors:  You-Zhou Chen; Xing-Shan Zhao; Jian-Song Yuan; Yan Zhang; Wei Liu; Shu-Bin Qiao
Journal:  Biol Sex Differ       Date:  2022-07-07       Impact factor: 8.811

4.  Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography.

Authors:  Christian Sohns; Samuel Sossalla; Jan D Schmitto; Claudius Jacobshagen; Björn W Raab; Silvia Obenauer; Lars S Maier
Journal:  Clin Res Cardiol       Date:  2010-02-21       Impact factor: 5.460

5.  Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients.

Authors:  F H Gietzen; C J Leuner; L Obergassel; C Strunk-Mueller; H Kuhn
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

Review 6.  The "1st septal unit" in hypertrophic obstructive cardiomyopathy: a newly recognized anatomo-functional entity, identified during recent alcohol septal ablation experience.

Authors:  Paolo Angelini
Journal:  Tex Heart Inst J       Date:  2007

7.  Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy.

Authors:  E Warwick Daw; Suet Nee Chen; Grazyna Czernuszewicz; Raffaella Lombardi; Yue Lu; Jianzhong Ma; Robert Roberts; Sanjay Shete; Ali J Marian
Journal:  Hum Mol Genet       Date:  2007-07-25       Impact factor: 6.150

8.  Comparison of long-term effect of dual-chamber pacing and alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Jan Krejci; Pavel Gregor; David Zemanek; Klaudia Vyskocilova; Karol Curila; Radka Stepanova; Miroslav Novak; Ladislav Groch; Josef Veselka
Journal:  ScientificWorldJournal       Date:  2013-11-11

9.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

Authors:  Hicham El Masry; Jeffrey A Breall
Journal:  Curr Cardiol Rev       Date:  2008-08

Review 10.  Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care.

Authors:  Lothar Faber
Journal:  Adv Med       Date:  2014-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.